Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | TGM2 | P21980 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 7/20 | 0.50 |
| ▸ | CA1 | P00915 | 6/20 | 0.50 |
| ▸ | CA9 | Q16790 | 6/20 | 0.50 |
| ▸ | CA12 | O43570 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15333772 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL12847513 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL11223742 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL404573 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL16217766 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL15494655 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL24771437 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL7147808 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL20516514 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL22927890 | 1.00 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210308162-A1 | NOVEL TLR4 INHIBITORS FOR THE TREATMENT OF HUMAN INFECTIOUS AND INFLAMMATORY DISORDERS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-10-07 | — | — | US | disclosed |
| US-10933077-B2 | TLR4 inhibitors for the treatment of human infectious and inflammatory disorders | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-03-02 | — | — | US | disclosed |
| US-10300083-B2 | TLR4 inhibitors for the treatment of human infectious and inflammatory disorders | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2019-05-28 | — | — | US | disclosed |
| EP-2703495-B1 | METHOD FOR DETECTING CANCER CELL USING FLUORESCENTLY LABELED L-GLUCOSE DERIVATIVE, AND CANCER CELL-IMAGING AGENT COMPRISING FLUORESCENTLY LABELED L-GLUCOSE DERIVATIVE | UNIV HIROSAKI (JP) | 2018-05-09 | — | — | EP | disclosed |
| US-20170095493-A1 | NOVEL TLR4 INHIBITORS FOR THE TREATMENT OF HUMAN INFECTIOUS AND INFLAMMATORY DISORDERS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-04-06 | — | — | US | disclosed |
| US-9532999-B2 | TLR4 inhibitors for the treatment of human infectious and inflammatory disorders | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-01-03 | — | — | US | disclosed |
| EP-1553101-B1 | N-ACETYLGLUCOSAMINE DERIVATIVES AND USE THEREOF | KAO CORP (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-20150250809-A1 | NOVEL TLR4 INHIBITORS FOR THE TREATMENT OF HUMAN INFECTIOUS AND INFLAMMATORY DISORDERS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2015-09-10 | — | — | US | disclosed |
| US-9072760-B2 | TLR4 inhibitors for the treatment of human infectious and inflammatory disorders | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2015-07-07 | — | — | US | disclosed |
| US-9045514-B2 | Methods for producing amino-substituted glycolipid compounds | DUPONT NUTRITION BIOSCIENCES APS (DK) | 2015-06-02 | — | — | US | disclosed |
| EP-0553297-A1 | PROCESS FOR THE PREPARATION OF GLYCOSYL PHOSPHATE TRIESTERS. | DU PONT (US) | 1993-08-04 | — | — | EP | disclosed |
| WO-1992009612-A1 | PROCESS FOR THE PREPARATION OF GLYCOSYL PHOSPHATE TRIESTERS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-06-11 | — | — | WO | disclosed |
| US-5095123-A | Phosphorylation | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-03-10 | — | — | US | disclosed |
| US-5037969-A | Protein modifiers and fractionating agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-08-06 | — | — | US | disclosed |
| EP-0317572-A4 | METHOD OF PREPARING MERACETYL OXAZOLINES. | GEN HOSPITAL CORP (US) | 1989-11-23 | — | — | EP | disclosed |
| EP-0317572-A1 | METHOD OF PREPARING PERACETYL OXAZOLINES | THE GENERAL HOSPITAL CORPORATION (US) | 1989-05-31 | — | — | EP | disclosed |
| US-4785084-A | REACTION WITH TRIFLUOROMETHANESULFONIC ACID TO FORM PERACETYL OXAZOLINE | THE GENERAL HOSPITAL CORPORATION (US) | 1988-11-15 | — | — | US | disclosed |
| WO-1988000951-A1 | METHOD OF PREPARING MERACETYL OXAZOLINES | THE GENERAL HOSPITAL CORPORATION (US) | 1988-02-11 | — | — | WO | disclosed |
| EP-0251304-A2 | Glycosyl derivatives and use thereof | Takeda Chemical Industries, Ltd. (JP) | 1988-01-07 | — | — | EP | disclosed |
| US-4554349-A | Aralkyl and aralkenyl glycosides as inhibitors of antigen-specific T-cell proliferation | MERCK & CO., INC. (US) | 1985-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150250809-A1 | NOVEL TLR4 INHIBITORS FOR THE TREATMENT OF HUMAN INFECTIOUS AND INFLAMMATORY DISORDERS | TLR4, TLR3, TLR1 | LMNA 3101/4885KMT2A 4485/4885POLB 4103/4885 |
| US-10300083-B2 | TLR4 inhibitors for the treatment of human infectious and inflammatory disorders | TLR4, TLR3, TLR1 | LMNA 2824/4885KMT2A 4503/4885POLB 4187/4885 |
| US-20170095493-A1 | NOVEL TLR4 INHIBITORS FOR THE TREATMENT OF HUMAN INFECTIOUS AND INFLAMMATORY DISORDERS | TLR4, TLR3, TLR1 | LMNA 3101/4885KMT2A 4485/4885POLB 4103/4885 |
| US-20210308162-A1 | NOVEL TLR4 INHIBITORS FOR THE TREATMENT OF HUMAN INFECTIOUS AND INFLAMMATORY DISORDERS | TLR4, TLR3, TLR1 | LMNA 3101/4885KMT2A 4485/4885POLB 4103/4885 |
| US-10933077-B2 | TLR4 inhibitors for the treatment of human infectious and inflammatory disorders | TLR4, TLR3, TLR1 | LMNA 2824/4885KMT2A 4503/4885POLB 4187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.